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Abstract 
Purpose: To elucidate the anticancer activity of Juglans regia leaf extract and its effect on cell cycle 
analysis, apoptosis and cancer cell morphology.  
Methods: Hexane extract of the leaves of Juglans regia was prepared by hot extraction. The anticancer 
activity of Juglans regia extract against human prostate cancer (PC3) cells was evaluated by MTT 
assay. Flow cytometry, using propidium iodide as a staining agent, was used to study the effect of the 
extract on cell cycle phase distribution.  Apoptosis induced by the extract was evaluated by Annexin V 
binding assay using flow cytometer. Alterations in cell morphology following apoptosis were studied by 
inverted phase contrast microscope.  
Results: The extract of Juglans regia exhibited a potent and dose-dependent anti-proliferative activity 
against human prostate cancer cells in vitro. The extract also induced significant apoptosis in these PC3 
cancer cells as revealed by annexin V binding assay as well as inverted phase contrast microscopy. It 
triggered a significant formation of apoptotic bodies after treatment with varying concentrations of the 
extract. Within 48 h of incubation, approximately 9.5, 15.5 and 26.3 % of the cells underwent early 
apoptosis after treatment with 5, 50 and 100 µg/mL of the extract, respectively. Similarly, 5.2, 11.2 and 
18.9 % of the cells underwent late apoptosis after treatment with 5, 50 and 100 µg/mL of the extract, 
respectively. Treatment with different concentrations of the extract for 48 h induced an increase in the 
population of cells in the sub-G1 phase and a slight decrease in the G2/M phase. 
Conclusion: The hexane extract of Juglans regia inhibits growth of human prostate cancer cells by 
inducing apoptosis with concomitant alterations in cell cycle phase distribution.  
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Prostate cancer (PC) is the second most 
widespread malignancy and the second leading 
cause of cancer-related deaths among men in 
many western countries including USA. 
Clinically, PC is generally diagnosed in men over 
50 years of age; with increasing life expectancy 
the prevalence of PC is likely to increase 
worldwide [1,2]. For PC chemoprevention at the 
present time there is considerable emphasis in 
identifying novel botanicals that selectively 
induce apoptosis and growth arrest of PC cells 
without producing cytotoxic effects on normal 
cells. Because of inadequate treatment options 
available for prostate cancer, there is an urgent 
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requirement for developing innovative preventive 
approaches for this malignancy. For a variety of 
reasons naturally occurring plant compounds and 
dietary substances are attaining increasing 
response as cancer chemopreventive agents [3-
7]. The majority of anticancer drugs are natural 
products or their derivatives. More than 200 
drugs derived from natural products are in 




J. regia belongs to the family Juglandaceae 
which includes 3 species: J. nigra, J. cinerea, 
and J. regia. Juglans regia L. commonly known 
as walnut tree is a well-known member of 
Juglans genus, constituting an important species 
of deciduous trees found primarily in temperate 
areas. J. regia extract contains ellagitannins 
which contains anti-cancer agent and with anti-
inflammatory properties. The key chemical 
composition of walnut is juglone (5-hydroxy-1, 4-
naphthoquinone), the toxic compound which is 
found only in green and fresh walnuts, but such 
property disappear in dried leaves. Other several 
phenolic compounds with antioxidant properties 
have been identified in J. regia leaves [10-13]. 
Walnut leaves are considered a source of 
healthcare compounds, and have been 
extensively used in traditional medicine for 
treatment of skin inflammations, hyperhidrosis 
and ulcers and for its anti-diarrheal, anti-
helmintic, antiseptic and astringent properties 
[12-14].  
 
The objective of the present study was to 
evaluate the anti-proliferative activity of the 
hexane extract of the leaves of Juglans regia 
against human prostate (PC3) cancer cells in 
vitro. We also studied the effect of the extract on 
cell cycle phase distribution as well as on the 
apoptosis induction using flow cytometry and 




Plant material and extraction procedure 
 
Juglans regia leaves were collected during July - 
August 2013 from a local site in Jianguo District, 
China. The plant material was identified by 
Professor Long Yuan-xi of the Huazhong 
Agricultural University, Wuhan, and a voucher 
specimen (no. DFST/HAU-0097654) was 
submitted to the University Herbarium. The plant 
material was confirmed by a well-known 
taxonomist. The leaves were thoroughly washed 
with tap water, shade-dried and then chopped 
into small pieces. Hexane (95 %) was used for 
hot extraction which was carried out for 4 h using 
a Soxhlet extraction apparatus. The extract was 
then concentrated under reduced pressure in a 
rotary evaporator at 45 oC and was then kept in a 
refrigerator at 4 oC prior to use. 
 
Chemicals and reagents 
 
Growth medium RPMI-1640 (Hangzhou Sijiqing 
Biological Products Co., Ltd, China), Minimum 
Essential Medium (MEM), Fetal Calf Serum 
(GIBCO), trypsin, penicillin, MTT, streptomycin, 
DMSO and phosphate buffer saline (PBS) were 
used in this study. MTT kit was obtained from 
Roche (USA). Annexin V-FITC-Propidium Iodide 
Apoptosis Detection Kit was purchased from 
Sigma (USA). All other chemicals and solvents 
used were of the highest purity grade. Cell 
culture plastic ware was bought from BD Falcon 
(USA). 
 
Cell lines and cell viability assay 
 
Human prostate carcinoma (PC3) cells were 
procured from the Shanghai Institute of Cell 
Resource Center of Life Science (Shanghai, 
China). All the cells were grown in a humidified 5 
% CO2 atmosphere at 37 oC in an incubator, and 
cultured in RPMI-1640 medium supplemented 
with 10 % heat-inactivated newborn calf serum, 
100 IU/ml penicillin and 100μg/mL streptomycin. 
Inhibition of cell proliferation of the extract was 
measured by the MTT assay. Briefly, PC3 cells 
were plated in 96-well culture plates (1 × 105 
cells/well) separately. After 24 h incubation, cells 
were treated with Juglans regia extract (5, 25, 
50, 75 and 100 μg/mL; eight wells per 
concentration) for 24 h; MTT solution (5 mg/mL) 
was then added to each well. After 4 h 
incubation, the formazan precipitate was 
dissolved in dimethyl sulfoxide (100 μL) and then 
the absorbance was measured in an ELISA 
reader (Thermo Molecular Devices Co., Union 
City, USA) at 570 nm. Cell viability ratio was 
calculated as in Eq 1. 
 
Cell viability (%) = {(Ac – At)/Ac}100 ………. (1) 
 
where Ac and At are the absorbance of control 
and treated cells, respectively. 
 
Cytotoxicity was expressed as the concentration 
of the extract inhibiting cell growth by 50 % (IC50 
value). 
 
Cell cycle phase distribution analysis by flow 
cytometry 
 
Human prostate carcinoma PC3 cells (1 × 106) 
were seeded in 60-mm dishes and subjected to 
various concentrations (5, 25, 50, 75 and 100 
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μg/mL) of the Juglans regia extract for 48 h. 
Floating and adherent cells were collected by 
trypsinization and washed twice with PBS. Cells 
were incubated in 70 % ethanol at -20 °C 
overnight, treated with 10 µg/mL RNase A, then 
stained with 2.0 µg/mL of propidium iodide. 
Finally the stained cells were analyzed and 
studied by flow cytometry at wavelength of 488 
nm (FACS Calibur instrument (BD Biosciences, 
San Jose, CA, USA) equipped with Cell Quest 
3.3 software). 
 
Annexin V binding assay  
 
We performed annexin V binding assay using 
flow cytometry to confirm apoptosis. The PC3 
cells were treated with Juglans regia extract (5, 
25, 50, 75 and 100 μg/mL) for 48 h. 
Subsequently, treated and untreated cells were 
harvested by trypsinization. Harvested cells were 
then incubated in annexin V-FITC (50 ng/mL) 
and propidium iodide (20 µg/mL), at room 
temperature for 30 min in the dark, and analysed 
using a FACS Calibur flow cytometer (BD 
Bioscience) taking a minimum 25,000 cells in 
each sample. 
 
Live cell morphology assay of apoptosis 
 
Apoptotic morphological characteristics of human 
prostate carcinoma cells were recorded with an 
inverted phase contrast microscope (IPCM) 
(Olympus, Japan) after treatment with various 
concentrations (5, 25, 50, 75 and 100 μg/mL) of 
the extract. Cells cultured with 0.5 % DMSO 




All the data were analysed using analysis of 
variance (ANOVA), followed by Dunnett’s test for 
pair-wise comparison. Mean values are 
presented with their standard deviation (SD). 
Statistical significance was defined as p < 0.05 




Anti-proliferative activity of Juglans regia 
extract 
 
Juglans regia leaf extract was evaluated for 
antiproliferative activity using the MTT assay 
against the human prostate carcinoma (PC3) 
cells for 24 h (Figure 1). The extract exhibited 
potent and dose-dependent cytotoxic activity 
against these cancer cells. The IC50 value of the 
extract was calculated to be 48.4 µg/mL. IC50 
value gives an indication of the potency of a 
drug/agent. As shown in Figure 1, 100 µg/mL 
extract exhibited a very strong anticancer effect 
at which approximately only 15 % of the cells 
were alive and 85 % cells were damaged. 
 
Effect of Juglans regia extract on cell cycle 
phase distribution 
 
Treatment with different concentrations of the 
extract for 48 h induced an increase in the 
population of cells in the sub-G1 phase and a 





Figure 1: Anti-proliferative activity of the hexane extract of Juglans regia against prostate cancer cells in vitro 
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Approximately 2.1 % of the control cells were in 
the sub-G1 phase, while approximately 6.5, 23.5 
and 35.2 % of the cells treated with 5, 50 and 
100 µg/mL of the extract concentration were in 
this phase respectively. 
 
Quantification of apoptotic cell death induced 
by Juglans regia extract  
 
To verify if this increase in the sub-G1 population 
of human prostate cancer cells was due to 
apoptosis, PC3 cells were labeled with FITC-
conjugated Annexin V and PI for flow cytometry 
analysis. The results of the flow cytometry study 
with Annexin V/FITC and PI showed that, within 
48 h of incubation, approximately 9.5 %, 15.5 % 
and 26.3 % of the cells underwent early 
apoptosis after treatment with 5, 50 and 100 
µg/mL of the extract respectively. Similarly, 5.2 
%, 11.2 % and 18.9 % of the cells underwent late 
apoptosis after treatment with 5, 50 and 100 
µg/mL of the extract respectively (Figure 3 and 
Figure 4). 
 
Apoptosis induced by Juglans regia extract 
 
The induction of apoptosis by Juglans regia 
extract was confirmed by studying apoptotic body 
formation using inverted phase contrast 
microscope. As shown in Figure 5, the formation 
of apoptotic bodies was observed 48 h post-
treatment in Juglans regia extract-treated cells. 





Figure 2: Cell cycle distribution of human prostate carcinoma (PC3) cells after treatment with 5.0 µg/ml (B), 50 
µg/ml (C) and 100 µg/ml (D) of Juglans regia extract for 48 h. The cells were treated with RNase and propidium 
iodide and then analyzed by flow cytometry. (A) represents negative control (DMSO solvent) 
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Figure 3: Dot plot of human prostate carcinoma (PC3) cells after exposure to 5, 50 and 100 µg/ml concentration 
of Juglans regia extract for 48 h and flow cytometry analysis with Annexin V-FITC versus PI. The divisions of the 
plots distinguish necrotic cells (Annexin V-/PI+, left upper quadrant) from early apoptotic cells (Annexin V+/PI-, 
right lower quadrant) and late apoptotic cells (Annexin V+/PI+, right upper quadrant). The plots in the figure are 
representative of 5 independent experiments 
 
 
Figure 4: Percentages of cells in apoptosis at each Juglans regia extract concentration. Cells in the bottom and 
top right quadrants of Figure 3 were summed to obtain the total number of apoptotic cells. Findings are presented 
as the mean of three similar experiments ± standard deviation 
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Figure 5: Juglans regia extract (B, C and D represent 5, 50 and 100 µg/ml concentration of the extract 
respectively while A represents negative control) induced cell apoptosis in human prostate carcinoma (PC3) cells 
is marked by apoptotic body formation and apoptotic DNA degradation. Apoptotic body formation was observed 




Prostate cancer (PC) is the second most wide-
spread malignancy and the second leading 
cause of cancer-related deaths among men in 
many Western countries including USA [1]. 
Clinically, PC is generally diagnosed in men over 
50 years of age; with increasing life expectancy 
the prevalence of PC is likely to increase 
worldwide. PC usually develops from androgen-
dependent to androgen-independent stage, 
making anti-androgen therapy unproductive, thus 
leading to a rise in metastatic potential [1,15]. 
Suppression of cancer development frequently 
involves modulation of signal transduction 
pathways, resulting in alterations in gene 
expression, arrest in cell cycle progression or 
apoptosis. Apoptotic cell death represents a 
universal and intricately efficient suicide pathway, 
considered as a perfect method for elimination of 
damaged cells [16]. Recently, the apoptosis 
signaling systems have been shown to provide 
encouraging targets for the development of novel 
anticancer agents [17]. Several plant-derived 
bioactive compounds are known to be 
chemopreventive agents inducing apoptosis in a 
number of experimental models of 
carcinogenesis. Thus induction of apoptosis is 
considered as a possible mechanism of chemo 
preventive agents [18-20]. 
 
In this study, the Juglans regia hexane extract 
was evaluated for its anticancer activity against 
human prostate PC3 cancer cells. The extract 
showed a dose-dependent inhibition of the 
cancer cells with 100 µg/mL of the extract 
producing the most potent growth inhibition. In 
order to further study the mechanism of the 
extract, we evaluated effect of the extract on cell 
cycle analysis, apoptosis induction using Annexin 
V binding assay as well as inverted phase 
contrast microscopy. The results revealed that 
the Juglans regia extract increased the fraction of 
sub-G1 cells in a dose-dependent manner along 
with a slight decrease in G2/M fraction of cells. 
The apoptosis assay revealed that the number of 
cells with both late and early apoptosis increases 





Juglans regia leaf extract induces potent growth 
inhibitory effects against human prostate cancer 
cells (PC3) by inducing apoptosis and by altering 
the cell cycle phase distribution in these cells. 
Therefore, the extract may find application in 
curbing prostate cancer and is a potential 
Li et al 
Trop J Pharm Res, March 2015; 14(3): 405  
 
complementary and alternative medicinal 
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